Primal Study

Precision Medicine Randomized Clinical Trial Comparing
Molecular Tumor Board Assisted Care to Usual Care (PRiMAL)

NCT05254795


This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.

Molecular Tumor Board

The Markey Cancer Center Molecular Tumor Board is a forum for experts to review genetic abnormalities to provide patient-specific targeted therapies.
Learn More

PRiMAL ClinicalTrials.gov Website

To learn more about the PRiMAL study, visit the ClinicalTrials.gov website.
NCT05254795
Learn More

Past issues of the PRiMAL Newsletter are available in the archives.

PRiMAL Newsletter Archive

Precision Medicine Symposium

UPCOMING MEETINGS

9th Annual Precision Medicine Symposium
Date TBA   |  Griffin Gate Marriott Resort and Spa

This symposium highlights clinical advances in precision medicine and cancer health disparities.

LEARN MORE

NCI Comprehensive Cancer Center - A Cancer Center Designated by the National Cancer Institute

Markey Cancer Center is designated by the National Cancer Institute as a Comprehensive Cancer Center – a distinction that recognizes our commitment to accelerating precision cancer research and care to patients. We are the first and only NCI-Comprehensive Cancer Center in Kentucky, and one of 57 in the nation.

LEARN MORE